Imagine a World Where metabolic balance is the norm,And patients live without compromise. " We are developing and delivering novel therapies for rare diseases to significantly improve the quality of life for patients and their families. learn more Our lead development program: two Phase 3 programs in congenital and tumor hyperinsulinism. View Our Pipeline Check out stories about how patients and their families address the day-to-day challenges of living with hyperinsulinism. View patient Voices Recent Press Releases view all Rezolute to Participate in the BTIG Virtual Biotechnology Conference 07/21/26 Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society 06/17/26 Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society 06/04/26
